ReviewPaediatric drugs2026
Pediatric Myocarditis: Challenges in Diagnosis and Treatment.
Review in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric heart failure in the era of cardio-immunology: inflammatory-immune context phenotypes, diagnosis, and targeted management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric myocarditis is a clinically diverse and often under-recognized inflammatory condition of the myocardium, with presentations that range from mild symptoms to acute heart failure. Advances in cardiac imaging, biomarker discovery, and molecular genetics have improved diagnostic precision and individualized care. Genetic studies indicate that 8-10% of pediatric patients with myocarditis carry pathogenic variants in cardiomyopathy-related genes, supporting the "double-hit" hypothesis where genetic predisposition interacts with viral or autoimmune triggers. This paradigm shift has underscored the relevance of precision medicine, emphasizing tailored management based on the underlying etiology and genetic background. While supportive care remains the foundation of therapy, including rest, hemodynamic monitoring, and guideline-directed medical therapy for heart failure, pharmacologic strategies are evolving. Corticosteroids are under investigation for modulating inflammation, with mixed results showing improvements in ventricular function but unclear survival benefits. Immunomodulatory agents, such as intravenous immunoglobulin and other immunosuppressive therapies, offer promise in reducing myocardial fibrosis and injury. Virus-specific therapies are increasingly utilized in confirmed viral myocarditis, improving outcomes in selected cases. Recent studies highlight the potential role of biologic agents targeting inflammatory pathways, such as interferons, interleukin modulators, and micro-RNA-based therapy in refractory cases. Despite limited pediatric-specific trial data, extrapolation from adult myocarditis studies continues to inform treatment direction. Continued translational research and pediatric-focused clinical trials are critical to optimizing treatment of myocarditis and improving long-term cardiac outcomes. Future investigations should focus on refining immunomodulatory strategies, identifying novel therapeutic targets, and enhancing risk stratification to improve individualized care.
Indexed as
Identifiers
41654696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.